3-[2-(cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-[1H]-benz[e]isoindol-2-yl)ethyl]-6-phenylthieno[3,2-d]-pyrimidine-2,4(1H,3H)-dione | 759436-61-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: 3-[2-(cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-[1H]-benz[e]isoindol-2-yl)ethyl]-6-phenylthieno[3,2-d]-pyrimidine-2,4(1H,3H)-dione
• 英文别名: rel-3-[2-[(3aR,9bR)-1,3,3a,4,5,9b-Hexahydro-6-methoxy-2H-benz[e]isoindol-2-yl]ethyl]-6-phenylthieno[3,2-d]pyrimidine-2,4(1H,3H)-dione；3-[2-[(3aS,9bS)-6-methoxy-1,3,3a,4,5,9b-hexahydrobenzo[e]isoindol-2-yl]ethyl]-6-phenyl-1H-thieno[3,2-d]pyrimidine-2,4-dione
• CAS: 759436-61-8
• 化学式: C₂₇H₂₇N₃O₃S
• 分子量: 473.596
• InChiKey: HKSUNNWTUBMNAB-NQIIRXRSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.09
• 重原子数：
  34.0
• 可旋转键数：
  5.0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  67.33
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为产物：
  描述：

  乙基3-氨基-5-苯基-2-噻吩羧酸酯 以 甲苯 为溶剂， 反应 3.0h， 生成 3-[2-(cis-6-methoxy-2,3,3a,4,5,9b-hexahydro-[1H]-benz[e]isoindol-2-yl)ethyl]-6-phenylthieno[3,2-d]-pyrimidine-2,4(1H,3H)-dione
  参考文献：
  名称：

  Structure−Activity Studies for a Novel Series of Bicyclic Substituted Hexahydrobenz[e]isoindole α_1A Adrenoceptor Antagonists as Potential Agents for the Symptomatic Treatment of Benign Prostatic Hyperplasia

  摘要：

  In search of a uroselective alpha (1A) subtype selective antagonist, a novel series of 6-OMe hexahydrobenz [e]isoindoles attached to a bicyclic heterocyclic moiety via a two-carbon linker was synthesized. It was found that in contrast to the previously described series of tricyclic heterocycles,l this bicyclic series has very specific requirements for the heterocyclic attachments. The most important structural features contributing to the alpha (1A)/alpha (1B) selectivity of these compounds were identified. In vitro functional assays for the al adrenoceptor subtypes were used to further characterize the most selective compounds, and in vivo models of vascular vs prostatic tone were used to assess uroselectivity. Compound 48 showed the highest degree of selectivity in the radioligand binding assays (56-fold), in the in vitro functional tests (80-fold), and for in vivo prostate selectivity (960-fold).

  DOI：

  10.1021/jm000541z